Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more
Market Cap & Net Worth: Evotec SE (EVOTF)
Evotec SE (PINK:EVOTF) has a market capitalization of $1.47 Billion ($1.47 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #6860 globally and #3765 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Evotec SE's stock price $8.27 by its total outstanding shares 177746121 (177.75 Million).
Evotec SE Market Cap History: 2016 to 2025
Evotec SE's market capitalization history from 2016 to 2025. Data shows growth from $920.72 Million to $1.47 Billion (8.33% CAGR).
Evotec SE Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Evotec SE's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.51x
Evotec SE's market cap is 1.51 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $920.72 Million | $164.51 Million | $27.53 Million | 5.60x | 33.44x |
| 2017 | $2.85 Billion | $257.63 Million | $24.26 Million | 11.05x | 117.39x |
| 2018 | $4.14 Billion | $375.40 Million | $84.17 Million | 11.03x | 49.20x |
| 2019 | $3.69 Billion | $446.44 Million | $38.16 Million | 8.26x | 96.66x |
| 2020 | $6.08 Billion | $500.92 Million | $6.28 Million | 12.14x | 968.29x |
| 2021 | $8.55 Billion | $618.03 Million | $215.51 Million | 13.83x | 39.66x |
| 2022 | $2.97 Billion | $751.45 Million | -$175.66 Million | 3.95x | N/A |
| 2023 | $4.37 Billion | $781.43 Million | -$83.91 Million | 5.60x | N/A |
| 2024 | $1.20 Billion | $796.97 Million | -$196.08 Million | 1.51x | N/A |
Competitor Companies of EVOTF by Market Capitalization
Companies near Evotec SE in the global market cap rankings as of March 18, 2026.
Key companies related to Evotec SE by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Evotec SE Historical Marketcap From 2016 to 2025
Between 2016 and today, Evotec SE's market cap moved from $920.72 Million to $ 1.47 Billion, with a yearly change of 8.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.47 Billion | +22.11% |
| 2024 | $1.20 Billion | -72.48% |
| 2023 | $4.37 Billion | +47.48% |
| 2022 | $2.97 Billion | -65.30% |
| 2021 | $8.55 Billion | +40.61% |
| 2020 | $6.08 Billion | +64.82% |
| 2019 | $3.69 Billion | -10.94% |
| 2018 | $4.14 Billion | +45.44% |
| 2017 | $2.85 Billion | +209.27% |
| 2016 | $920.72 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Evotec SE was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.47 Billion USD |
| MoneyControl | $1.47 Billion USD |
| MarketWatch | $1.47 Billion USD |
| marketcap.company | $1.47 Billion USD |
| Reuters | $1.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.